AbbVie annual total assets
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Total Assets Growth & History (ABBV)
AbbVie's total assets was $133.96B for fiscal 2025.
View full AbbVie company overviewAbbVie annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $133.96B | −$1.20B | −0.89% |
| 2024 | 2024-12-31 | $135.16B | $450.0M | +0.33% |
| 2023 | 2023-12-31 | $134.71B | −$4.09B | −2.95% |
| 2022 | 2022-12-31 | $138.81B | −$7.72B | −5.27% |
| 2021 | 2021-12-31 | $146.53B | −$4.04B | −2.68% |
| 2020 | 2020-12-31 | $150.56B | $61.45B | +68.96% |
| 2019 | 2019-12-31 | $89.11B | $29.76B | +50.15% |
| 2018 | 2018-12-31 | $59.35B | −$11.43B | −16.15% |
| 2017 | 2017-12-31 | $70.79B | $4.69B | +7.09% |
| 2016 | 2016-12-31 | $66.10B | $13.05B | +24.60% |
| 2015 | 2015-12-31 | $53.05B | $25.54B | +92.82% |
| 2014 | 2014-12-31 | $27.51B | −$1.69B | −5.77% |
| 2013 | 2013-12-31 | $29.20B | $2.19B | +8.11% |
| 2012 | 2012-12-31 | $27.01B | — | — |
AbbVie quarterly total assets
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $135.12B | −$2.07B | −1.51% |
| Q1 2026 | 2026-03-31 | $136.46B | $298.0M | +0.22% |
| Q4 2025 | 2025-12-31 | $133.96B | −$1.20B | −0.89% |
| Q3 2025 | 2025-09-30 | $133.90B | −$9.52B | −6.64% |
| Q2 2025 | 2025-06-30 | $137.18B | −$4.75B | −3.35% |
| Q1 2025 | 2025-03-31 | $136.16B | −$12.71B | −8.54% |
| Q4 2024 | 2024-12-31 | $135.16B | $450.0M | +0.33% |
| Q3 2024 | 2024-09-30 | $143.42B | $7.20B | +5.29% |
| Q2 2024 | 2024-06-30 | $141.94B | $6.57B | +4.85% |
| Q1 2024 | 2024-03-31 | $148.87B | $14.33B | +10.65% |
| Q4 2023 | 2023-12-31 | $134.71B | −$4.09B | −2.95% |
| Q3 2023 | 2023-09-30 | $136.22B | −$5.10B | −3.61% |
| Q2 2023 | 2023-06-30 | $135.37B | −$7.82B | −5.46% |
| Q1 2023 | 2023-03-31 | $134.54B | −$8.67B | −6.05% |
| Q4 2022 | 2022-12-31 | $138.81B | −$7.72B | −5.27% |
| Q3 2022 | 2022-09-30 | $141.32B | −$7.53B | −5.06% |
| Q2 2022 | 2022-06-30 | $143.19B | −$4.79B | −3.23% |
| Q1 2022 | 2022-03-31 | $143.21B | −$7.29B | −4.84% |
| Q4 2021 | 2021-12-31 | $146.53B | −$4.04B | −2.68% |
| Q3 2021 | 2021-09-30 | $148.86B | −$763.0M | −0.51% |
| Q2 2021 | 2021-06-30 | $147.97B | −$1.56B | −1.04% |
| Q1 2021 | 2021-03-31 | $150.50B | $59.30B | +65.02% |
| Q4 2020 | 2020-12-31 | $150.56B | $61.45B | +68.96% |
| Q3 2020 | 2020-09-30 | $149.62B | $90.18B | +151.71% |
| Q2 2020 | 2020-06-30 | $149.53B | $92.39B | +161.68% |
| Q1 2020 | 2020-03-31 | $91.20B | $34.43B | +60.65% |
| Q4 2019 | 2019-12-31 | $89.11B | $29.76B | +50.15% |
| Q3 2019 | 2019-09-30 | $59.44B | −$6.72B | −10.16% |
| Q2 2019 | 2019-06-30 | $57.14B | −$4.50B | −7.30% |
| Q1 2019 | 2019-03-31 | $56.77B | −$12.57B | −18.13% |
| Q4 2018 | 2018-12-31 | $59.35B | −$11.43B | −16.15% |
| Q3 2018 · Sep 30 | 2018-09-30 | $66.16B | −$2.68B | −3.89% |
| Q2 2018 | 2018-06-30 | $61.64B | −$5.35B | −7.99% |
| Q1 2018 | 2018-03-31 | $69.34B | $3.68B | +5.60% |
| Q4 2017 | 2017-12-31 | $70.79B | $4.69B | +7.09% |
| Q3 2017 | 2017-09-30 | $68.84B | $2.21B | +3.32% |
| Q2 2017 | 2017-06-30 | $66.99B | −$217.0M | −0.32% |
| Q1 2017 | 2017-03-31 | $65.66B | $11.94B | +22.23% |
| Q4 2016 | 2016-12-31 | $66.10B | $13.05B | +24.60% |
| Q3 2016 | 2016-09-30 | $66.63B | $11.79B | +21.51% |
| Q2 2016 | 2016-06-30 | $67.21B | $13.36B | +24.80% |
| Q1 2016 | 2016-03-31 | $53.72B | $27.02B | +101.21% |
| Q4 2015 | 2015-12-31 | $53.05B | $25.54B | +92.82% |
| Q3 2015 | 2015-09-30 | $54.83B | $26.38B | +92.70% |
| Q2 2015 | 2015-06-30 | $53.85B | $24.81B | +85.42% |
| Q1 2015 | 2015-03-31 | $26.70B | −$1.96B | −6.83% |
| Q4 2014 | 2014-12-31 | $27.51B | −$1.69B | −5.77% |
| Q3 2014 | 2014-09-30 | $28.45B | $202.0M | +0.71% |
| Q2 2014 | 2014-06-30 | $29.05B | $1.14B | +4.07% |
| Q1 2014 | 2014-03-31 | $28.66B | $1.49B | +5.48% |
| Q4 2013 | 2013-12-31 | $29.20B | $2.19B | +8.11% |
| Q3 2013 | 2013-09-30 | $28.25B | — | — |
| Q2 2013 | 2013-06-30 | $27.91B | — | — |
| Q1 2013 | 2013-03-31 | $27.17B | — | — |
| Q4 2012 | 2012-12-31 | $27.01B | — | — |
AbbVie total assets trends
Over the last five fiscal years, AbbVie's total assets decreased from $150.56B to $133.96B, a change of −$16.61B. The latest reported quarter, Q2 2026, shows $135.12B.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...